Studies teclistamab and talquetamab in relapsed or refractory multiple myeloma
Observes how teclistamab and talquetamab work in adults with relapsed multiple myeloma.
Plain-language title generated from the registry record
Registry title: Study on the Clinical Efficacy of Teclistamab and Talquetamab
Key facts
- Where
- Bonheiden, Brussels, Charleroi, Edegem, Ghent, Hasselt, Hornu, Kortrijk, Leuven, Liège, Mons, Roeselare, Sint-Niklaas, and Yvoir, BelgiumSee the 17 sites
Where in Belgium
- ImeldaBonheiden, BelgiumNot yet recruiting
- Institut Jules BordetBrussels, BelgiumTaking people
- UCL - Saint LucBrussels, BelgiumTaking people
- Grand Hopital de CharleroiCharleroi, BelgiumTaking people
- Universitair Ziekenhuis Antwerpen (Uza)Edegem, BelgiumTaking people
- Algemeen Ziekenhuis Maria Middelares (AZMM)Ghent, BelgiumTaking people
- Universitair Ziekenhuis Gent (Uz Gent)Ghent, BelgiumTaking people
- JESSA ZiekenhuisHasselt, BelgiumTaking people
- EpicuraHornu, BelgiumTaking people
- AZ GroeningeKortrijk, BelgiumTaking people
- UZ Leuven GasthuisbergLeuven, BelgiumTaking people
- CHR CitadelleLiège, BelgiumTaking people
- CHU LiègeLiège, BelgiumTaking people
- CHU Ambroise ParéMons, BelgiumTaking people
- AZ DeltaRoeselare, BelgiumTaking people
- VitazSint-Niklaas, BelgiumTaking people
- Chu Ucl NamurYvoir, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaire Ziekenhuizen KU Leuven
- Trial code
- NCT06477783
- Record updated
- 25 September 2026
- Original description
The aim of this study is to assess the clinical efficacy of the anti-BCMA/CD3 bispecific antibody teclistamab and anti-GPRC5D/CD3 bispecific antibody talquetamab in a prospective, real-life setting in Belgium.Read full original descriptionShow less
Prospective Observational Study on the Clinical Efficacy of Teclistamab and Talquetamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium
The aim of this study is to assess the clinical efficacy of the anti-BCMA/CD3 bispecific antibody teclistamab and anti-GPRC5D/CD3 bispecific antibody talquetamab in a prospective, real-life setting in Belgium.
Inclusion: Age 18 years or older; Written informed consent; Has a diagnosis of relapsed and refractory multiple myeloma; Has already received at least three previous treatments; Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody; Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria; Anticipated to start treatment with teclistamab or talquetamab per routine clinical care or has started with teclistamab treatment ≤28 days before intended screening visit.
Exclusion: Has started teclistamab or talquetamab treatment >28 days before intended screening visit; Inability or unwillingness to comply with the study protocol, including scheduled visits, treatment plans, or follow-up requirements.